Positive CLL Data For AstraZeneca's BTK Inhibitor Prompts Early ASCEND Trial End
The Calquence Phase III ASCEND trial met its primary endpoint at interim analysis in relapsed or refractory chronic lymphocytic leukemia and thus will stop early.
You may also be interested in...
The PAOLA-1 study has shown the benefit of Lynparza for ovarian cancer patients regardless of tumor mutation status which should firm up the drug's dominance in the PARP inhibitor space.
In a move which AstraZeneca PLC says "completes its transformation in oncology," it is acquiring a 55% stake in privately held Dutch biotech Acerta Pharma BV for $4bn, made up of $2.5bn now and $1.5bn later. The deal also includes an option to acquire the remainder of the company for a further $3bn.
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.